Sofo pricing…equally for GT2 and GT3 would be very politically correct and GILD surely needs this kind of positive PR material, so they might do the gesture.
That could be accomplished by setting a ceiling on the cumulative price per patient, as Genentech once did for Avastin.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.